Capmatinib in MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma with Extensive Central Nervous System Metastasis

Several selective mesenchymal–epithelial transition (MET) inhibitors have recently demonstrated favorable systemic efficacy in MET exon 14 skipping mutation-positive non-small cell lung cancer. However, there are limited data on their efficacy against central nervous system (CNS) metastasis, especia...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Tae Woo, Lee, Kyung Mi, Lee, Seung Hyeun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9441579/
https://www.ncbi.nlm.nih.gov/pubmed/36072511
http://dx.doi.org/10.2147/OTT.S382722

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9441579/
https://www.ncbi.nlm.nih.gov/pubmed/36072511
http://dx.doi.org/10.2147/OTT.S382722

Ejemplares similares